Literature DB >> 10321905

Production of 1alpha,25-dihydroxy-3-epi-vitamin D3 in two rat osteosarcoma cell lines (UMR 106 and ROS 17/2.8): existence of the C-3 epimerization pathway in ROS 17/2.8 cells in which the C-24 oxidation pathway is not expressed.

M L Siu-Caldera1, H Sekimoto, A Weiskopf, P Vouros, K R Muralidharan, W H Okamura, J Bishop, A W Norman, M R Uskoković, I Schuster, G S Reddy.   

Abstract

The secosteroid hormone 1alpha,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3] is metabolized into calcitroic acid through the carbon 24 (C-24) oxidation pathway. It is now well established that the C-24 oxidation pathway plays an important role in the target tissue inactivation of 1alpha,25(OH)2D3. Recently, we reported that 1alpha,25(OH)2D3 is also metabolized into 1alpha,25-dihydroxy-3-epi-vitamin D3 [1alpha,25(OH)2-3-epi-D3] through the carbon 3 (C-3) epimerization pathway in human keratinocytes, human colon carcinoma cells (Caco-2), and bovine parathyroid cells. In a previous study, it was demonstrated that 1alpha,25(OH)2-3-epi-D3 when compared to 1alpha,25(OH)2D3 was less active in stimulating intestinal calcium absorption, calcium mobilization from bone, and induction of calbindin D28k. These findings suggest that the C-3 epimerization pathway, like the C-24 oxidation pathway, may play a role in the target tissue inactivation of 1alpha,25(OH)2D3. In this study, we determined the relationship between the C-24 oxidation and the C-3 epimerization pathways by investigating the metabolism of 1alpha,25(OH)2D3 in two rat osteosarcoma cell lines (UMR 106 and ROS 17/2.8). These two cell lines differ from each other in their ability to metabolize 1alpha,25(OH)2D3 through the C-24 oxidation pathway. It has been previously reported that the C-24 oxidation pathway is expressed only in UMR 106 cells but not in ROS 17/2.8 cells. The results of our present study provide new evidence that both cell lines possess the ability to metabolize 1alpha,25(OH)2D3 into 1alpha,25(OH)2-3-epi-D3 through the C-3 epimerization pathway. Our results also reconfirm the findings of previous studies indicating that UMR 106 cells are the only ones which express the C-24 oxidation pathway out of the two cell lines studied. Furthermore, this study reveals for the first time that the C-3 epimerization pathway may become an alternate metabolic pathway for the target tissue inactivation of 1alpha,25(OH)2D3 in some cells, such as ROS 17/2.8, in which the C-24 oxidation pathway is not expressed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10321905     DOI: 10.1016/s8756-3282(99)00019-8

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  5 in total

1.  Case report: Three patients with substantial serum levels of 3-epi-25(OH)D including one with 3-epi-25(OH)D2 while on high-dose ergocalciferol.

Authors:  Donald Wiebe; Neil Binkley
Journal:  J Clin Endocrinol Metab       Date:  2014-01-29       Impact factor: 5.958

Review 2.  The serum vitamin D metabolome: What we know and what is still to discover.

Authors:  Robert C Tuckey; Chloe Y S Cheng; Andrzej T Slominski
Journal:  J Steroid Biochem Mol Biol       Date:  2018-09-08       Impact factor: 4.292

3.  1α,25(OH)2-3-epi-vitamin D3, a natural physiological metabolite of vitamin D3: its synthesis, biological activity and crystal structure with its receptor.

Authors:  Ferdinand Molnár; Rita Sigüeiro; Yoshiteru Sato; Clarisse Araujo; Inge Schuster; Pierre Antony; Jean Peluso; Christian Muller; Antonio Mouriño; Dino Moras; Natacha Rochel
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

4.  Misleading measures in Vitamin D analysis: a novel LC-MS/MS assay to account for epimers and isobars.

Authors:  Iltaf Shah; Ricky James; James Barker; Andrea Petroczi; Declan P Naughton
Journal:  Nutr J       Date:  2011-05-14       Impact factor: 3.271

Review 5.  Epimers of Vitamin D: A Review.

Authors:  Bashar Al-Zohily; Asma Al-Menhali; Salah Gariballa; Afrozul Haq; Iltaf Shah
Journal:  Int J Mol Sci       Date:  2020-01-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.